Mutational signatures and their association with cancer survival and gene expression in multiple cancer types
International Journal of Cancer · 2025-01 · 156 (1) · 114-129
DOI: 10.1002/ijc.35148 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 28.08.2024. Verfasst von Peeter Karihtala und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Mutation, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oulu University Hospital, Helsinki University Hospital, Oulun Yliopistollinen Sairaala.
Abstract (Originalsprache)
Different endogenous and exogenous mutational processes cause specific patterns of somatic mutations and mutational signatures. Although their biological research has been intensive, there are only rare studies assessing the possible prognostic role of mutational signatures. We used data from The Cancer Genome Atlas to study the associations between the activity of the mutational signatures and four survival endpoints in 18 types of malignancies. We further explored the prognostic differences according to, for example, the HPV status in head and neck squamous cell carcinomas and smoking status in lung cancers. The predictive power of the signatures over time was evaluated with a dynamic area under the curve model, and the links between mutational signature activities and differences in gene expression patterns were analyzed. In 12 of 18 studied cancer types, we identified at least one mutational signature whose activity predicted survival outcomes after adjusting for the established prognostic factors. For example, overall survival was associated with the activity of mutational signatures in nine cancer types and disease‐specific survival in seven cancer types. The clock‐like signatures SBS5 and SBS40 were most commonly associated with survival endpoints. The genes of the myosin binding protein and melanoma antigen families were among the most substantially dysregulated genes between the signatures of low and high activity. The differences in gene expression also revealed various enriched pathways. Based on these data, specific mutational signatures associate with the gene expression and have the potential to serve as strong prognostic factors in several cancer types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
- Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.
- Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Department of Medical and Clinical Genetics, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- HUSLAB Laboratory of Genetics, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
- K. Albin Johansson Cancer Research Fellow, Foundation for the Finnish Cancer Institute, Helsinki, Finland.
ORCID-Profile: Peeter Karihtala, Outi Kilpivaara
Förderung
- Oulu University Hospital
- Helsinki University Hospital
- Oulun Yliopistollinen Sairaala
Zitieren
APA
Karihtala, P., Kilpivaara, O., & Porvari, K. (2025). Mutational signatures and their association with cancer survival and gene expression in multiple cancer types. International Journal of Cancer, 156(1), 114-129. https://doi.org/10.1002/ijc.35148
Vancouver
Karihtala P, Kilpivaara O, Porvari K. Mutational signatures and their association with cancer survival and gene expression in multiple cancer types. International Journal of Cancer. 2025;156(1):114-129. doi:10.1002/ijc.35148
BibTeX
@article{Karihtala2025,
author = {Karihtala, Peeter and Kilpivaara, Outi and Porvari, Katja},
title = {Mutational signatures and their association with cancer survival and gene expression in multiple cancer types},
journal = {International Journal of Cancer},
year = {2025},
volume = {156},
number = {1},
pages = {114--129},
doi = {10.1002/ijc.35148}
}
EUVIMED